Health and Me

Ishita Roy

Eli Lilly's Popular Weight Loss Zepbound Price Goes Down, Now More Accessible

<span>Eli Lilly</span> announced a significant reduction in cash princes of its popular weight loss drug, <span>Zepbound</span>, which are sold through its direct to consumer platform, LillyDirect. This move will expand the ongoing efforts by both the company and the Trump administration to make obesity and diabetes medications for affordable for Americans. 

The announcement comes right after its rival <span>Novo Nordisk</span> decided to introduce additional cash price discounts on its popular obesity and diabetes drugs. 

<h2>What Is In For Patients? New, Lower Monthly Costs </h2>

Starting Monday, patients who pay cash and have a valid prescription can purchase Zepbound’s starting-dose single-dose vials for as low as $299 per month, reduced from the previous $349. The next dose, 5 milligrams, will cost $399 per month, while all higher doses will now be $449 per month, down from $499.

These discounts are substantial considering Zepbound’s list price of about $1,086 per month. Combined with inconsistent insurance coverage for weight-loss medications in the U.S., the high list price has long posed an access barrier for many patients.

<h2>Push To Expand Access of Weight Loss And Diabetes Drugs For Those Who Need It</h2>

The price cuts come on the heels of President Donald Trump’s recently signed agreements with Eli Lilly and Novo Nordisk. These deals aim to make GLP-1 drugs, widely used for weight loss and Type 2 diabetes, more affordable and accessible.

Under the agreements, the government will pay reduced prices for the medications, Medicare will for the first time cover obesity drugs for certain patients, and Americans will be able to purchase discounted doses through the government’s upcoming direct-to-consumer platform, <span>TrumpRx</span>, launching in January, 2026.

However, the Trump–Eli Lilly agreement focuses specifically on lowering future prices for multi-dose pen versions of Zepbound after they receive FDA approval. That makes Monday’s announcement especially meaningful: patients can benefit immediately from discounted pricing on the currently available single-dose vials.

Eli Lilly emphasized its commitment to widening access to obesity treatments. “We will keep working to provide more options, expanding choices for delivery devices and creating new pathways for access—so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities.

Zepbound is a dual agonist, targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-action approach activates two pathways that amplify insulin secretion, slow gastric emptying, and reduce appetite, ultimately aiding in weight loss. Intresitngly, this drug was linked ot other benefits besides weight loss. Research has found that Zepbound may also offer additional health benefits, including improved cardiovascular health and potential effects on obstructive sleep apnea.

The results of the clinical trials were published on Dec 4. It showed that participants taking Zepbound lost an average of 50.3 lbs, compared to 33.1 lbs with Wegovy. Moreover, nearly 32% of those on Zepbound achieved at least a 25% reduction in body weight, while only 16.1% of Wegovy users reached this milestone.

However, the efficacy of these medicines are variable for different individual. Health experts have repeatedly cautioned that individual responses to each medication can differ. Factors such as medical history and body composition play a role in how well a person responds to these medications, so one may be more effective than the other for certain individuals.

Health Conditions A-Z

health

eli lilly zepbound

eli lilly weight loss

zepbound

eli lilly

trumprx

novo nordisk

health news

health news USA

New Warning On Ozempic Use In Australia, After Study Links Popular Weight Loss Drugs With Suicidal Thoughts

Before You Take Paracetamol, NHS Advises These Five Groups To Check With A Doctor

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Eli Lilly announced a significant reduction in cash princes of its popular weight loss drug, Zepbound, which are sold through its direct to consumer platform, LillyDirect. This move will expand the ongoing efforts by both the company and the Trump administration to make obesity and diabetes medications for affordable for Americans. The announcement comes right after its rival Novo Nordisk decided to introduce additional cash price discounts on its popular obesity and diabetes drugs. What Is In For Patients? New, Lower Monthly Costs Starting Monday, patients who pay cash and have a valid prescription can purchase Zepbound’s starting-dose single-dose vials for as low as $299 per month, reduced from the previous $349. The next dose, 5 milligrams, will cost $399 per month, while all higher doses will now be $449 per month, down from $499.These discounts are substantial considering Zepbound’s list price of about $1,086 per month. Combined with inconsistent insurance coverage for weight-loss medications in the U.S., the high list price has long posed an access barrier for many patients.Push To Expand Access of Weight Loss And Diabetes Drugs For Those Who Need ItThe price cuts come on the heels of President Donald Trump’s recently signed agreements with Eli Lilly and Novo Nordisk. These deals aim to make GLP-1 drugs, widely used for weight loss and Type 2 diabetes, more affordable and accessible.Under the agreements, the government will pay reduced prices for the medications, Medicare will for the first time cover obesity drugs for certain patients, and Americans will be able to purchase discounted doses through the government’s upcoming direct-to-consumer platform, TrumpRx, launching in January, 2026.However, the Trump–Eli Lilly agreement focuses specifically on lowering future prices for multi-dose pen versions of Zepbound after they receive FDA approval. That makes Monday’s announcement especially meaningful: patients can benefit immediately from discounted pricing on the currently available single-dose vials.Eli Lilly emphasized its commitment to widening access to obesity treatments. “We will keep working to provide more options, expanding choices for delivery devices and creating new pathways for access—so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities.How Does Zepbound Work?Zepbound is a dual agonist, targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-action approach activates two pathways that amplify insulin secretion, slow gastric emptying, and reduce appetite, ultimately aiding in weight loss. Intresitngly, this drug was linked ot other benefits besides weight loss. Research has found that Zepbound may also offer additional health benefits, including improved cardiovascular health and potential effects on obstructive sleep apnea.The results of the clinical trials were published on Dec 4. It showed that participants taking Zepbound lost an average of 50.3 lbs, compared to 33.1 lbs with Wegovy. Moreover, nearly 32% of those on Zepbound achieved at least a 25% reduction in body weight, while only 16.1% of Wegovy users reached this milestone.However, the efficacy of these medicines are variable for different individual. Health experts have repeatedly cautioned that individual responses to each medication can differ. Factors such as medical history and body composition play a role in how well a person responds to these medications, so one may be more effective than the other for certain individuals.